Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients
Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients: a Randomised, Double-blind, Placebo-controlled Trial
Barzilai Medical Center
60 participants
May 5, 2021
INTERVENTIONAL
Conditions
Summary
Poor ovarian response population of ART are considered the biggest challenge for providers. Hitherto, no one protocol has been proven to be effect in this subgroup of IVF patients. Metoclopramide belongs to the antiemetic group, used for motion sickness and during early gestation for hyperemesis gravidarum. The mechanism of action is antagonisim to dopamine receptors. We hypothesize than by blocking dopamine receptors and decreasing the dopaminergic tone there is a possibility to increase the sensitivity of ovarian response to gonadotropins during controlled ovarian stimulation and result in increased oocyte retrival.
Eligibility
Inclusion Criteria1
- Poor response according to "Bologna criteria"
Exclusion Criteria3
- Allergy to metoclopramide
- Prolactinemia
- Women treated with dopamine agonists
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Metoclopramide 10 mg BID
Placebo 10 mg BID
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03560583